Pathogenesis of musculoskeletal deficits in children and adults with inflammatory bowel disease by Steell, Lewis et al.
nutrients
Review
Pathogenesis of Musculoskeletal Deficits in Children and
Adults with Inflammatory Bowel Disease
Lewis Steell 1, Stuart R. Gray 1, Richard K. Russell 2, Jonathan MacDonald 3, John Paul Seenan 3,
Sze Choong Wong 4 and Daniel R. Gaya 5,*


Citation: Steell, L.; Gray, S.R.;
Russell, R.K.; MacDonald, J.; Seenan,
J.P.; Wong, S.C.; Gaya, D.R.
Pathogenesis of Musculoskeletal
Deficits in Children and Adults with
Inflammatory Bowel Disease.
Nutrients 2021, 13, 2899. https://
doi.org/10.3390/nu13082899
Academic Editor: Lynnette Ferguson
Received: 17 June 2021
Accepted: 20 August 2021
Published: 23 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8QQ, UK;
lewis.steell@glasgow.ac.uk (L.S.); Stuart.Gray@glasgow.ac.uk (S.R.G.)
2 Department of Paediatric Gastroenterology, Royal Hospital for Sick Children, Edinburgh EH16 4TJ, UK;
Richard.russell@nhslothian.scot.nhs.uk
3 Department of Gastroenterology, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK;
Jonathan.macdonald@ggc.scot.nhs.uk (J.M.); johnpaul.Seenan@ggc.scot.nhs.uk (J.P.S.)
4 Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow G51 4TF, UK;
jarod.wong@glasgow.ac.uk
5 Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow G4 0SF, UK
* Correspondence: daniel.gaya@ggc.scot.nhs.uk
Abstract: Musculoskeletal deficits are among the most commonly reported extra-intestinal manifes-
tations and complications of inflammatory bowel disease (IBD), especially in those with Crohn’s
disease. The adverse effects of IBD on bone and muscle are multifactorial, including the direct effects
of underlying inflammatory disease processes, nutritional deficits, and therapeutic effects. These
factors also indirectly impact bone and muscle by interfering with regulatory pathways. Resultantly,
individuals with IBD are at increased risk of osteoporosis and sarcopenia and associated muscu-
loskeletal morbidity. In paediatric IBD, these factors may contribute to suboptimal bone and muscle
accrual. This review evaluates the main pathogenic factors associated with musculoskeletal deficits
in children and adults with IBD and summarises the current literature and understanding of the
musculoskeletal phenotype in these patients.
Keywords: inflammatory bowel disease; Crohn’s disease; bone; muscle; osteoporosis; inflammation
1. Introduction
Musculoskeletal deficits are among the most common extra-intestinal manifestations
and complications of inflammatory bowel disease (IBD), especially in those with Crohn’s
disease (CD). Specifically, patients with IBD are at an increased risk of osteoporosis, a
systemic disorder characterised by low bone mass and deterioration of bone microarchitec-
ture, with consequent increased risk of fractures throughout their lifetime [1]. In adults
without underlying chronic disease, osteoporosis is primarily an age-related disease of
abnormal bone metabolism, whereby excessive bone resorption results in net bone loss.
This is especially common in postmenopausal women [2]. In contrast, secondary osteo-
porosis relates to bone loss that occurs because of other factors, such as chronic disease,
exposure to medications that alter bone metabolism, or impaired mobility [3]. In growing
children with chronic disease, the underlying pathophysiology of secondary osteoporosis is
mainly due to inadequate skeletal development, rather than bone loss per se [4]. Poor bone
accrual during childhood may lead to the attainment of lower peak bone mass as adults.
Specifically in paediatric inflammatory diseases such as IBD, multiple factors including
underlying disease activity, undernutrition and exposure to systemic glucocorticoids may
contribute to poor bone mass accrual. As peak bone mass is a critical determinant of future
skeletal morbidity risk, these individuals may incur an increased risk of osteoporosis later
in life.
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On top of the well-established bone defects, emerging studies in the paediatric and
adult IBD show that muscle mass and function are low compared to healthy peers [5,6].
These muscle deficits may contribute to overall disease activity and are adversely associated
with responsiveness to IBD therapies [7,8] and postoperative morbidity [9,10]. Throughout
the lifespan, it is known that there is close bi-directional crosstalk between muscle and
bone [11]. In IBD, factors including chronic inflammation, nutritional deficits, and use of
long-term glucocorticoids have direct and indirect adverse effects on both muscle and bone
(Figure 1). This review aims to summarise the latest understanding of these factors and
their associations with musculoskeletal deficits in children and adults with IBD, primarily
focusing on CD.
Figure 1. Factors associated with musculoskeletal deficits in children and adults with inflammatory
bowel disease (IBD). Solid line = promoter; dashed line = inhibitor.
2. Pathogenesis of Musculoskeletal Deficits in IBD
2.1. Inflammation/Cytokines
Pro-inflammatory cytokines perpetuate gastrointestinal inflammation and tissue de-
struction in IBD while regulating extra-intestinal manifestations of the disease, including
bone and muscle deficits. The role of inflammation in the pathogenesis of skeletal deficits in
IBD has been highlighted by reduced bone mass in newly diagnosed cohorts of treatment
naïve paediatric IBD patients [12–14] and the report of osteoporotic vertebral fracture as
the presenting feature of CD in an adolescent [15].
Several cytokines are known to be chronically elevated in the serum of individu-
als with IBD, such as TNF-α, IL-1β, and IL-6 inhibit osteoblast function (responsible for
bone formation) and promote osteoclastogenesis (responsible for bone resorption) [16–18].
TNF-α appears to be the master regulator of bone loss in IBD as it promotes expression
of receptor activator of nuclear factor κB ligand (RANKL) from osteogenic cells and in-
dependently interacts with RANKL as a potent stimulator of osteoclastogenesis, via the
nuclear factor kappa B (NF-κB) signaling pathway [19,20]. In what appears to be an attempt
to maintain bone homeostasis, the decoy RANK receptor, osteoprotegerin (OPG), which
inhibits osteoclastogenesis, has been found to be elevated in the plasma of IBD patients [21].
However, this mechanism appears insufficient to reverse RANKL and TNF-α mediated
bone resorption, as OPG levels were inversely associated with bone density [21]. During a
disease flare, elevated serum RANKL was observed in CD compared to healthy controls,
highlighting the influence of inflammation on the RANKL/OPG pathway in perpetuating
bone resorption [17]. Inflammatory cytokines also adversely affect bone formation in IBD.
Serum from treatment naïve CD patients inhibited osteoblast function in vitro, indicating
a biochemical component of CD that negatively regulates bone formation [22,23], with
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other studies demonstrating the pivotal role of IL-6 [24]. In a murine model of colitis
(Piroxicam treated IL-10 knock out mice), the elevation of gut expressed inflammatory
cytokines, including TNF-α, IL-1, IL-6 and IL-17A were associated with a reduction in
circulating levels of bone formation markers, increased bone resorption, and reduction
in trabecular thickness at the tibia [25]. The interaction between activated immune cells
and cytokines with bone cells and metabolism is a continually evolving area of research.
Several cytokines upregulated in IBD have been found to influence bone turnover in vitro,
in animal studies, and in other inflammatory pathologies (reviewed elsewhere [26]).
TNF-α and IL-6 are also key regulators of muscle loss in CD, a pathway shared with
aging. Circulating TNF-α and IL-6 are increased in healthy elderly adults and are nega-
tively associated with muscle mass and function [27]. These and other pro-inflammatory
cytokines are elevated in the serum of quiescent IBD compared with controls [5,23,28].
While cytokines play a key role in normal skeletal muscle homeostasis and regeneration, in
the context of dysregulated immune function as that in CD, they moderate and contribute to
skeletal muscle loss. Increased levels of TNF-α and IL-1β result in the activation of NF-κB
pathways to accelerate protein degradation [29] and decrease expression of pro-myogenic
factor, MyoD [30]. Excessive TNF-α may also reduce the regenerative capacity of skeletal
muscle satellite cells via inflammation-induced mitogen-activated protein kinase signalling
that leads to epigenetic alterations and inhibition of myogenesis [31,32]. Ultimately, these
pathways will promote inflammatory mediated muscle loss in IBD with reduced muscle
mass and function.
2.2. Nutrition
Individuals with IBD are at increased risk of sub-optimal nutritional status which
can itself impact bone and muscle. The aetiology of poor nutritional status in IBD is
multifactorial and includes disease activity associated with anorexia, exclusion diets,
medication-induced nausea, pain from strictures, and malabsorption from both active
disease and small bowel resections. However, both undernutrition and overnutrition are
known to be associated with adverse effects on the musculoskeletal system. Historically,
rapid and unsolicited weight loss was a presenting symptom of disease in both CD and
ulcerative colitis (UC), indicative of nutritional deficiency. For example, malnutrition as
defined by a body mass index (BMI) Z-score < −2 SDS was observed in approximately
30% of paediatric CD patients at diagnosis in one prospective study, reducing to 15% at the
long-term follow-up [33]. Some historical estimates suggest 60–80% of CD and 30–60% of
UC patients present with undernutrition at disease diagnosis [34–36]. In paediatric CD, low
weight Z-score was associated with low height Z-score, and the amelioration of nutritional
status after anti-TNF-α therapy was associated with improved linear growth irrespective
of pubertal progression [37].
Dietary intake and composition are intrinsically linked to disease management in IBD,
as exemplified by the efficacy of exclusive enteral nutrition (EEN) in inducing remission and
mucosal healing in CD [38,39] and other potential therapeutic dietary interventions [40]. A
proportion of patients with IBD may develop food aversions or follow self-imposed exclu-
sionary diets to prevent perceived exacerbation of disease symptoms [41–43]. This could
lead to inadequate dietary intake and subsequent micro and macronutrient deficiencies,
which have been observed in adults with quiescent disease [44]. Dietary calcium intake
was found to be lower in patients with IBD from a dietary questionnaire study, due to
perceived lactose intolerance [45]. In another study, low calcium intake was associated with
reduced femoral neck bone density in a cohort of young adults with CD [46]. Furthermore,
pro-inflammatory cytokines have been shown to directly interfere with appetite hormones
which may reduce hunger and subsequently dietary intake in IBD [47].
Inadequate dietary intake has been reported in patients with both active and inactive
IBD [42,48–50]. During active phases of the disease, elevated metabolic expenditure due to
perpetual immune activation may also contribute to malnutrition, further compounding
nutritional deficits and contributing to musculoskeletal loss. Separate from inadequate
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dietary intake, intestinal malabsorption can also be a particular concern to some patients
with CD. Patients with significant small bowel CD can present a particular challenge to
clinicians; active stricturing small bowel disease will more often present with nutritional
issues as malabsorption and post-prandial pain (leading to food avoidance) are additive in
their detrimental effects. Moreover, after repeated resective surgeries (more of a historical
issue that now rarely occurs) such patients can become dependent on parental nutrition
and require lifelong close follow-up and monitoring to prevent the many complications of
undernutrition in this setting.
Contrary to the typical undernutrition observed in IBD, clinicians managing these
patients are encountering an increasing frequency of patients who are overweight and
obese, in line with the obesity epidemic present in the general population. Prolonged
systemic glucocorticoid therapy by itself could of course contribute to weight gain. This
creates a separate issue of overnutrition that may contribute to bone and muscle defects.
Recent studies show that the prevalence of obesity among adults with IBD is estimated at
10–50% [51–53], whereas 10–30% of paediatric IBD patients are obese at diagnosis [54,55].
Obesity is associated with poor bone microarchitecture relative to body weight [56] thought
in part to be driven by increased levels of inflammatory adipocytokines. While obesity
is generally associated with slightly increased muscle mass, muscle quality is adversely
affected by the associated accumulation of intramuscular fat, which leads to poor muscle
function and is a risk factor for musculoskeletal morbidity [57].
BMI is generally used as a clinical marker of nutritional status. However, it is an
insensitive measure of adiposity as abnormal body composition, characterised by low lean
mass and maintained or increased fat mass, is common in paediatric and adult IBD [58].
Resultantly, ‘normal’ BMI can also be falsely reassuring as increased adiposity, especially
visceral adiposity, despite BMI in the normal ranges have been described in IBD [59,60].
Visceral adipose tissue expresses pro-inflammatory adipocytokines such as TNF-α, IL-1β,
and IL-6 that may further perpetuate systemic inflammation and contribute to bone and
muscle loss in CD [28]. The potential role of increased visceral adiposity on disease activity
itself requires further research but may highlight the necessity of avoiding overnutrition in
IBD patients. In the clinic, estimates of fat mass and lean mass using skin calipers, mid-arm
circumference and, if available, bioimpedance may help identify specific areas requiring
action. Use of these and the development of novel outcome measures that accurately
reflect nutritional status in IBD require further research as the nutritional status may be an
important confounder of musculoskeletal health.
2.3. Glucocorticoids
Systemic glucocorticoids are commonly administered as first-line induction therapy
for moderate to severe IBD in adult and paediatric patients. Glucocorticoids are effective
in achieving clinical remission in IBD; however, they are associated with systemic toxicity,
including profound and devastating effects on bone and muscle. Chronic glucocorticoid
exposure can lead to muscle atrophy and glucocorticoid-induced osteoporosis with an
increased risk of fragility fractures [61–63]. In children, glucocorticoid exposure can also
lead to delayed pubertal development and inhibition of linear growth [64,65]. Given that
linear growth and pubertal development are also major drivers of bone development
during childhood, it is not surprising that factors that inhibit growth and puberty lead to
inadequate bone accrual.
In adults, glucocorticoid-induced bone and muscle loss occur in a rapid, dose-depen-
dent manner. Glucocorticoids induce preferential loss of metabolically active trabecular
bone [66], highlighted by the increased risk of vertebral fractures in glucocorticoid treated
populations even with short-term exposure. Primarily, glucocorticoids-induced bone loss
occurs via protracted reduction of bone formation, via inhibition of osteoblast function [61].
They have also been observed to induce apoptosis in osteoblasts and osteocytes [67]. An
initial increase in bone resorption is also observed as glucocorticoids stimulate increased
expression of RANKL from osteoblastic cells while downregulating OPG expression [68].
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Additionally, glucocorticoids reduce the capacity of mature osteoblasts to synthesise type I
collagen, leading to a reduced volume of the bone matrix for mineralisation [69]. Extra-
skeletal effects of glucocorticoids with an impact on the skeleton include impaired intestinal
absorption of calcium and phosphate, impaired vitamin D metabolism, and increased renal
calcium excretion, which may lead to secondary hyperparathyroidism [61].
In children, glucocorticoids directly inhibit linear growth via peripheral and central
mechanisms which in turn can impair bone development. Glucocorticoids cause local
insensitivity to growth hormone (GH) and insulin-like growth factor 1 (IGF-1) at the growth
plate by disrupting GH/IGF-1 receptors in chondrocytes [70]. Glucocorticoids also inhibit
IGF-1 signalling which impedes proliferation and upregulates apoptosis locally in chon-
drocytes at the growth plate [71]. Chronic exposure to glucocorticoids in children can
also contribute to delayed puberty via the development of hypogonadotropic hypogo-
nadism due to gonadotrophic releasing hormone (GnRH) suppression [72]. The use of
glucocorticoids in paediatric IBD patients is therefore avoided where possible, or very
closely monitored and tapered as quickly as is clinically viable to minimise the potential
for growth or pubertal disturbance.
The catabolic effects of glucocorticoids within the muscle may also negatively influ-
ence bone. The muscle wasting properties of glucocorticoids can be observed as little
as seven days after initiation of therapy [73]. Glucocorticoids regulate muscle protein
balance by inhibiting muscle protein synthesis and accelerating proteolysis, resulting in net
catabolism. Exogenous glucocorticoids inhibit muscle protein synthesis through reduced
expression of hepatic and muscle IGF-1 and upregulate skeletal muscle atrophy-related
genes including muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx) [74,75].
All the above has led to cautious and limited use of glucocorticoids in IBD and
early institution of steroid-sparing measures. Indeed, avoidance of repeated courses of
glucocorticoids is a key performance indicator in the audit of UK IBD units [76]. While
there is no doubt that even a short course of glucocorticoids has a negative impact on bone,
it must be emphasised that inflammation itself is also a driver of bone loss or attenuation
of bone accrual. Therefore, if glucocorticoid remains the only therapeutic strategy that
may lead to induction of remission in patients with moderate or severe disease, this option
should be used for as short a duration as possible.
2.4. Vitamin D
Vitamin D has pleiotropic physiological functions but is primarily recognised for
its role in the regulation of calcium homeostasis and bone metabolism. Low levels of
vitamin D can lead to secondary hyperparathyroidism, whereby excessive parathyroid
hormone expression accelerates bone turnover with subsequent reductions in bone strength.
Additionally, vitamin D plays an integral role in both innate and adaptive immunity
(extensively reviewed elsewhere [77]), including in the maintenance of intestinal barrier
function and inhibition of pro-inflammatory cytokine expression through suppression of
T-cell activation. Resultantly, low circulating vitamin D levels may indirectly affect skeletal
outcomes via the loss of these immunomodulating functions. In IBD, several factors can
contribute to vitamin D deficiency, including intestinal malabsorption, poor dietary intake,
and lack of sunlight exposure (due to both inactivity during disease flares and following
medical advice on avoidance while taking immunosuppressive medications). Low levels of
vitamin D are more common in IBD compared to the general population and more common
in CD compared to UC [78]. Prior studies have observed vitamin D insufficiency (serum
25-hydroxyvitamin D [25-OHD] < 50 nmol/L) or deficiency (<25 nmol/L) in 30–70% of
adult IBD patients [5,44,78–80].
While there is growing interest in the link between vitamin D and skeletal muscle
mass and function, a direct causal role for low vitamin D in IBD-associated musculoskeletal
pathology has not been clearly established. To date, no studies have investigated the direct
role of vitamin D status on skeletal muscle of patients with IBD. However, low serum vita-
min D3 was associated with impaired activation of muscle protein synthesis pathways in
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the skeletal muscle of young adults with CD [81]. Additionally, muscle function improved
in children with IBD after long-term vitamin D supplementation, suggesting a potential
role that warrants future investigation [82]. One study found levels of the active form of
vitamin D (1,25-dihydroxy vitamin D) to be higher in the serum of CD patients compared
to UC, and to be inversely associated with bone density in CD [83]. The authors postulated
that conversion of 25-OHD to 1,25-dihydroxy vitamin D may be greater in CD to support
immune function and the observed association with skeletal outcomes possibly reflects
the higher inflammatory burden of CD rather than a specific skeletal effect. Neverthe-
less, low serum 25-OHD was previously associated with accelerated bone turnover in a
cross-sectional study of adults with CD [84] and was reported as a risk factor for low bone
density in another cohort [85]. Other studies in IBD, however, have failed to report an
association between vitamin D status and bone density [86]. Still, improvements in bone
density have been observed after long-term vitamin D and calcium supplementation in
children [82] and adults [87] with IBD. A treatment effect of vitamin D is unlikely to be
observed if the population is already vitamin D replete. In clinical practice, optimization
of vitamin D levels is paramount in those with severe disease and/or prolonged therapy
with glucocorticoids.
2.5. GH/IGF-1
Chronic inflammatory diseases such as IBD can interfere with the systemic GH/IGF-1
axis. Inflammatory cytokines, glucocorticoid exposure, and poor nutrition all adversely
affect GH/IGF-1 with subsequent impacts on health outcomes. The GH/IGF-1 axis is
a primary regulator of linear skeletal growth and muscle accrual during childhood and
puberty [88]. The GH/IGF-1 axis also plays a critical role in the maintenance of muscle-
bone outcomes across the adult lifespan. GH stimulates the proliferation of osteoblasts
and chondrocytes [89,90], promotes bone formation in mature osteoblasts [90] and induces
local IGF-1 expression at the growth plate [88,91], all of which stimulate linear growth.
In skeletal muscle, the anabolic actions of GH are mediated by systemic and local IGF-1,
which stimulate muscle protein synthesis and reduce protein degradation [92].
In paediatric CD, faltering linear growth is a concern that often precedes gastrointesti-
nal symptoms and may be linked to a range of systemic abnormalities in the GH/IGF-1
axis, including a relative state of hormone insensitivity or hormone insufficiency [93].
Systemic inflammation, use of glucocorticoids, and poor nutrition inhibit multiple aspects
of the endocrine GH/IGF-1 axis [94]. Pro-inflammatory cytokines such as IL-6 and TNF-α
reduce IGF-1 through inhibition of GH signal transduction [95] and downregulation of
GH receptor expression [96], respectively, in hepatocytes. IL-6 also increases proteolysis
of insulin-like growth factor binding protein3 (IGFBP3), which inhibits IGF-1/IGFBP3
complex formation and leads to increased IGF-1 clearance [97]. While inflammation, poor
nutrition, and the use of glucocorticoids can have a negative impact on the systemic
GH/IGF-1 axis, it is also now well known that such factors can also play a role in growth
failure by a direct impact on the growth plate.
Generally, normal levels of GH secretion with reduced IGF-1 and IGF binding proteins
(IGFBPs) in paediatric CD have been reported in published studies, which reflects a state of
systemic GH insensitivity [98]. However, as mentioned, a range of different abnormalities
in GH/IGF-1 have been observed in these growing children [93]. Circulating IGF-1 and
IGFBP3 levels are also lower, especially during active disease, in adults with CD, although
partially normalised after treatment with glucocorticoids in multiple reports [99,100]. To
the best of our knowledge, there are no published studies evaluating the impact of the
abnormal GH/IGF-1 axis on musculoskeletal health outcomes in adults with IBD. In a
preliminary study, recombinant human growth hormone injections for moderate to severe
CD in adults were associated with lower disease activity index at four months [101].
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2.6. Delayed Puberty and Sex Steroid Deficiency
Sex steroids are essential for bone and muscle accrual in adolescents and maintenance
of these outcomes in adults. Puberty is a critical period of bone and muscle growth that
is moderated by the associated surge in sex steroid production, accompanied by an in-
crease in the amount and amplitude of GH. Bone mass approximately doubles between
the pre-pubertal and young adult age, and 90% of peak bone mass will be attained by late
adolescence. Oestrogen is essential for the maturation and mineralisation of bone and
the closure of epiphyseal growth plates in both sexes [102], and oestrogen deficiency in
adults is associated with rapid bone loss, as observed in postmenopausal women [103].
The actions of oestrogen in bone are manifold, including the proliferation of osteoblast
precursors, stimulating bone formation in mature osteoblasts, and inhibiting osteoclasto-
genesis [102,104,105]. Androgens also have important roles in skeletal development and
maintenance and are responsible for the sexual dimorphism of bone. Androgens promote
osteoblast proliferation and upregulate androgen receptors in growth plate osteoblasts,
stimulate longitudinal and radial bone growth, and preserve adult bone directly via inter-
action with androgen receptors and indirectly via aromatization to oestrogens [106,107].
Deficiency of sex steroids is associated with reductions in bone strength and increased risk
of fracture in both sexes [108,109].
The insidious onset of paediatric IBD typically manifests in the pre or early pubertal
age and can delay the timing of puberty. Delayed puberty is more common among
children with CD and less so in those with UC. Adolescents with CD who fail to achieve
disease remission or who experience frequent disease relapses are at the greatest risk of
pubertal delay. Studies have used various maturational markers to assess pubertal delay in
paediatric CD, including bone age [98], age at menarche [110], and age at pubertal growth
spurt [111]; all of whom showed some delay compared to healthy controls or published
normative data.
Similarly, nutritional deficits, inflammatory cytokines, and prolonged use of glucocor-
ticoids are implicated in the pathogenesis of pubertal delay in adolescents with CD [112].
Chronic undernutrition is associated with reduced fat mass, with subsequently reduced
levels of leptin [113], which is an essential hormone for the advent of puberty. In studies
using animal models of CD, however, reduced leptin was not the sole regulator of delayed
puberty in CD and pro-inflammatory cytokines were found to have a direct role, likely
through their inhibitory actions on gonadotropin secretion [114]. This hypothesis was sup-
ported by a subsequent study in children with active CD who were treated with anti-TNF-α
induction therapy. Anti-TNF-α therapy led to a reduction of pro-inflammatory cytokines
and increasing levels of circulating sex hormones and gonadotropins, independent of
changes in body composition [115].
Few studies have been conducted to assess sex steroid deficiency in adults with IBD.
Serum testosterone has been reported lower in men with CD compared to healthy controls,
but clinically relevant testosterone deficiency was uncommon [116,117]. Low levels of
oestradiol compared to controls have also been reported, although no association between
oestradiol and bone density or turnover markers was observed [117]. In clinical practice,
assessment of gonadal function (i.e., sex steroids and gonadotrophins) is important in
adults with IBD who present with fragility fractures and should be part of the routine
assessment in the metabolic bone clinic, as recommended by the International Osteoporosis
Foundation [118]. Sex steroid replacement therapy (with oestrogen or testosterone) may be
indicated if evidence of hypogonadism is identified.
2.7. Low Muscle Mass
Muscle and bone health are intricately related across the lifespan and their inherently
linked physiology means one should not be considered independently of the other. The
appropriate muscle outcome measure that can be incorporated into routine clinical care is
still unknown. Low muscle mass, defined as a low skeletal muscle index on lumbar CT scan,
has been reported in >50% of adult CD patients at diagnosis [119] and during a disease
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flare [10]. Similarly, using DXA, 60% of CD patients in remission had low muscle mass and
91% of these had concurrent osteopenic bone density T-scores [120]. We recently reported
approximately 20% lower muscle cross-sectional area of the mid-thigh in young adults
with childhood-onset CD, despite mild disease activity, compared to healthy controls [5].
Despite observing no deficits in trabecular microarchitecture between CD and controls in
our study, muscle area was positively associated with trabecular bone volume in the CD
group. Impaired activation of muscle protein synthesis pathways in young adults with
CD was observed in one mechanistic study that may partly explain the observed muscle
deficits [81]. Despite this, however, it remains unclear whether muscle deficit is inherent to
CD or sequelae of inadequate disease control and associated lifestyle factors.
In paediatric IBD, deficits in muscle mass Z-scores are common among newly diag-
nosed patients [6,12,14,121,122] and those with established disease [12,123,124]. Effective
control of underlying disease, however, leads to only partial improvement in muscle mass
Z-scores and persistent deficits have been observed after EEN [121] and anti-TNF-α ther-
apy [123,124]. While there are no longitudinal studies of muscle function in paediatric IBD
with follow-up from adolescence to adulthood, our recent study of low muscle mass in
well-controlled young adults with childhood-onset CD [5], together with the published
data in paediatric CD, leads us to believe that muscle deficits may persist long-term.
2.8. Physical Inactivity
Physical activity and exercise regulate bone largely via the influence of mechanical
loading. Bone tissue is sensitive to its biomechanical environment and adapts accordingly
to mechanical loading or disuse, as described by Frost’s Mechanostat theory [125]. Bone
adaptation occurs secondary to mechanical loading to optimise bone mass and geometry
in relation to functional demands. In the context of reduced or absent mechanical loading,
rapid bone loss occurs in adults and bones fail to adequately develop in children [126,127].
Low levels of habitual physical activity and exercise are highlighted in observational
data from self-reported [128–130] and accelerometry [131,132] studies in children and adults
with IBD. In one accelerometry study, however, similar adherence to the recommended
guidelines of 60 min per day of moderate to vigorous physical activity (MVPA) between
adolescents with IBD and healthy age- and sex-matched controls was reported (31% vs 38%,
respectively) [133]. However, due to underlying disease and other contributing risk factors,
low-level adherence to MVPA is likely to disproportionately affect the musculoskeletal
health of those with IBD. Individuals with IBD experience several barriers that limit their
participation in physical activity and exercise, including chronic fatigue, abdominal and
joint pain, and increased urgency [128,129,134]. Negative associations between disease
activity and inflammatory markers with physical activity have also been reported in
CD [131,134]. Few studies have assessed the associations between physical activity and
musculoskeletal outcomes in IBD, although one observed a positive association between
accelerometry measured MVPA and bone density in adolescents [135].
The potential role of exercise in alleviating musculoskeletal burden in IBD has been
little studied to date. In two exercise intervention studies, twelve months of low-impact
core strengthening exercise [136] and six months of combined resistance and impact train-
ing [137] elicited mild improvements in bone density outcomes in adults with quiescent
or mild CD. The latter resistance-based exercise intervention also successfully increased
muscle function parameters by up to 50% in CD [137]. No studies have yet evaluated the
effects of an exercise intervention on musculoskeletal outcomes in paediatric IBD, despite
its potential to augment bone and muscle development. Research into incorporating physi-
cal activity as part of the care package of patients with IBD, especially early on following
the diagnosis, is needed.
3. Clinical Studies of Bone Health in IBD
Several imaging studies have been employed attempting to elucidate the muscu-
loskeletal phenotype in different IBD populations. The majority of published studies
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in IBD have employed dual-energy absorptiometry (DXA) for the assessment of bone
density. Given that short stature and delayed growth and puberty are more common in
paediatric chronic diseases like IBD, areal bone density will under-estimate bone mass
and therefore the need for appropriate size adjustment is now recognised. As mentioned,
this is performed by volumetric adjustment of spine bone density data or adjusting for
height, lean mass, or bone age for bone density data at other sites [138–140]. Peripheral
quantitative computed tomography (pQCT) gives insight into the volumetric bone density
of the trabecular and cortical bone and is not size-dependent. In addition, information
on bone geometry is provided. High-resolution imaging modalities like high-resolution
peripheral quantitative computed tomography (HR-pQCT) and MRI provide more detailed
information on bone microarchitecture, which previously could only be attained from
bone biopsies.
The greater risk of adverse musculoskeletal health in CD compared to UC is reflected
in the preponderance of CD patients included in published bone imaging studies. The
complexity of contributing factors to bone health is highlighted by some conflicting data
in adult studies, whereas the skeletal phenotype appears more consistent in studies of
paediatric IBD. Tables 1 and 2 summarise published studies of bone phenotype in paediatric
and adult IBD, respectively.
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The currently understood skeletal phenotype in paediatric IBD, predominantly in pae-
diatric CD, is characterised by deficits in cortical bone geometry with low volumetric bone
density (meaning adjusted for size) but maintained or slightly elevated cortical volumetric
bone density. Abnormalities are evident at diagnosis in paediatric IBD, with deficits in
total areal bone density [6,13,14,143], trabecular volumetric bone density [6,12,122], and
cortical thickness [6,12,14,122] observed in DXA and pQCT studies. Adverse skeletal out-
comes have been demonstrated independently of linear growth or pubertal delay in studies
that reported low DXA and pQCT Z-scores in IBD when adjusted for height [6,86], bone
size [58,122], or bone age delay [142]. Prospective studies have failed to report normal-
ization of bone deficits after long-term follow-up in paediatric CD patients [6,122] or in
those treated with EEN [121] or anti-TNF-α [123,124,141], suggesting that even with mod-
ern treatment strategies low-grade chronic inflammation may still be present. Currently,
little is known regarding microarchitectural parameters in paediatric IBD, as no in vivo
high-resolution imaging studies have been performed exclusively in this population. How-
ever, one study analysed trans-iliac bone biopsies in a small cohort of newly diagnosed
IBD patients (n = 20) and found normal trabecular bone volume despite cortical deficits,
inhibited bone turnover activity, and low volumetric bone density [14].
In adults with IBD, imaging studies of bone health have been almost exclusively
conducted using DXA, excluding two high-resolution pQCT (HR-pQCT) [144,145] and
one high-resolution MRI study from our own group [5]. The skeletal phenotype in adults
with IBD is less clear, as some conflicting data exists between studies which may relate
to the heterogeneity of the patient population studied, including age at assessment, dura-
tion of disease, treatment strategies (particularly the frequency of use of glucocorticoids
therapy), and skeletal sites studied. Nonetheless, most study data indicate low areal bone
density, particularly at the lumbar spine and hip regions [146,147,149,151]. This was further
highlighted in a recent meta-analysis that reported mean difference in areal bone density
Z-scores of -0.52 (95%CI: −0.71, −0.32) and −0.45 (95%CI: −0.62, −0.29) at the lumbar
spine and femoral neck, respectively, in adults with IBD [152]. This was coupled with
an increased global risk of fracture in adults with IBD compared to controls (RR: 1.38
(95%CI: 1.11, 1.73)) [152]. In another population-based study, a higher likelihood of osteo-
porosis in IBD compared to healthy age and sex-matched controls was reported (OR: 1.47
(95%CI: 1.2, 1.78)) [146]. Even in studies with no overall deficits in areal bone density
Z-scores in IBD, the prevalence of osteopenia remains high at 25−35% [148–150]. In adults
with quiescent CD and established osteopenia (n = 23), bone biopsy histomorphometry
highlighted an overall reduction in bone formation activity and associated trabecular
thinning to be the primary pathogenic cause of skeletal deficits [153]. Similar findings of
reduced bone formation compared to healthy controls were reported in another historic
bone histology study of adults with IBD and established osteoporosis (n = 19) [154].
Imaging assessments of skeletal macro and microstructure is less common in adults
compared to paediatric IBD. Two HR-pQCT studies reported deficits in trabecular microar-
chitecture, volumetric bone density, and cortical geometry, in young [144] and middle-
aged [145] adults with IBD. Conversely, we recently reported no deficits in trabecular
microarchitecture or cortical geometry in a cohort of young adults with mild or inac-
tive childhood-onset CD compared to healthy age and sex-matched controls, using high-
resolution MRI [5]. Our data suggest that children with CD may be able to recover any
skeletal deficits incurred earlier in the disease course with good disease management
using contemporary management strategies [155]. Such improvements have been pre-
viously reported in adults with strictly treated CD who had increased bone density at
long-term follow-up [87]. Conversely, DXA [59,156] and HR-pQCT [144] studies reported
low area bone density and microarchitectural parameters in cohorts including all or some
young adults with childhood-onset IBD. In contrast to our recent published study, most
published studies represent patients of a previous era in terms of disease management
often with a long duration of exposure to high-dose glucocorticoids. Further prospective,
high-resolution imaging studies are required to understand the progression of micro and
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macrostructural characteristics of bone in contemporary IBD cohorts especially in relation
to nutritional and newer therapeutic strategies.
4. Future Directions
The persistence of musculoskeletal deficits in children and adults with IBD, par-
ticularly CD, despite advances in disease management and pharmacological therapies,
highlights the need for research into effective therapeutic interventions which may include
nutritional, lifestyle and pharmacological approaches. Research into understanding the
patients who are at greatest risk of poor musculoskeletal outcomes using a genetic and
epigenetic approach may allow the introduction of personalised therapies in the future.
In adults with IBD treated with glucocorticoid, the use of anti-resorptive (i.e., os-
teoclast targeting) bisphosphonate therapy is associated with attenuated bone loss and
reduced fracture risk compared to non-treated controls [157]. In the clinical setting, the
use of intravenous bisphosphonates is recommended following identification of fragility
fracture (i.e., low trauma long bone fracture or vertebral fracture) [158]. Intravenous bis-
phosphonates are, however, associated with first dose acute reaction side effects which may
be commoner and more severe in those with chronic disease and those treated with gluco-
corticoid. Newer anti-resorptive therapy using monoclonal antibodies targeting RANKL
(Denosumab), has been shown to improve bone outcomes better than classic bisphospho-
nate therapy [159], is approved for use in glucocorticoid-induced osteoporosis, and is not
associated with first dose reactions. Inhibition of RANKL may have an additional impact
on skeletal muscle with early clinical data showing a reduction in the risk of falls and
improved markers of sarcopenia in elderly patients [160]. Additionally, Denosumab was
recently found to reduce colonic expression of pro-inflammatory cytokines and modulate
disruption of the microbiome in a murine model of colitis mimicking CD [161], suggesting
a potential role for RANKL in disease pathogenesis. Despite this, Denosumab remains
relatively unexplored in IBD and further investigation of its impact on bone, muscle and
disease outcomes in pre-clinical and human IBD studies is required. In addition, the
safety of the use of this strategy especially upon discontinuation of therapy should also be
considered in research studies.
Particularly in younger IBD patients at risk of musculoskeletal morbidity, the role
of non-pharmacological approaches like nutritional support and exercise therapy as an
adjunct to current IBD treatment strategies should be explored in high-quality clinical
trials. Future research on how these interventions can be incorporated into the routine
clinical care of IBD patients is also important to facilitate maximum impact on health and
disease outcomes.
5. Conclusions
Multiple factors which include the underlying disease activity, nutritional issues, and
use of glucocorticoids can impact musculoskeletal outcomes via diverse mechanisms in
children and adults with IBD. Many patients despite good IBD symptom control have
persistent deficits in muscle and bone health in published cohorts. Research into strategies
to improve future musculoskeletal outcomes in IBD focusing on optimising disease targets
beyond symptoms, plus improving nutritional status and beneficial lifestyle measures
should now be prioritised.
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